Metformin: Ongoing Journey with Superdrug Revolution

Amr Ahmed EL-Arabey ¹ * , Mohnad Abdalla ², Wafa Ali Eltayb ³

Cited by CrossRef: 17

1- Tseng C. Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus. Biomolecules. 2021;11(10):1405 [Crossref]

2- Hassan S, Bedir E, Hamza A, Ahmed A, Ibrahim N, El-Ghany M, Sayed N, Eimera B, Salama M, Mohamed E, Mohamed D. The Dual Therapeutic Effect of Metformin Nuclei Based Drugs Modified with One of Tulbaghia Violacea Extract Compounds. SSRN Journal. 2022; [Crossref]

3- Pisano C, Benedetto U, Ruvolo G, Balistreri C. Oxidative Stress in the Pathogenesis of Aorta Diseases as a Source of Potential Biomarkers and Therapeutic Targets, with a Particular Focus on Ascending Aorta Aneurysms. Antioxidants. 2022;11(2):182 [Crossref]

4- Cohen D, Giaccagli M, Herzfeld J, González L, Cuasnicú P, Da Ros V. Metabolic syndrome and male fertility disorders: Is there a causal link?. Rev Endocr Metab Disord. 2021;22(4):1057 [Crossref]

5- Tseng C. The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin. Pharmaceuticals. 2023;16(2):224 [Crossref]

6- Nørgaard M, Darvalics B, Thomsen R. Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study. BMJ Open. 2020;10(12):e041875 [Crossref]

7- Dalman R, Wanhainen A, Mani K, Modarai B. Top 10 candidate aortic disease trials. J Intern Med. 2020;288(1):23 [Crossref]

8- EL‐Arabey A, Abdalla M. Metformin and COVID‐19: A novel deal of an old drug. Journal of Medical Virology. 2020;92(11):2293 [Crossref]

9- Tseng C. Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study. Otolaryngol--head neck surg. 2023;168(6):1389 [Crossref]

10- Tseng C. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus. Biomolecules. 2021;11(8):1226 [Crossref]

11- Chen R, Chen J, Chen M, Zhou S, Jiang P. Metformin suppresses proliferation and glycolysis of gastric cancer by modulating ADAMTS12. Genes and Environ. 2024;46(1) [Crossref]

12- El-Arabey A, Zhang H, Abdalla M, Al-Shouli S, Alkhalil S, Liu Y. Metformin as a promising target for DPP4 expression: computational modeling and experimental validation. Med Oncol. 2023;40(10) [Crossref]

13- Tseng C. The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review. World J Mens Health. 2022;40(1):11 [Crossref]

14- Yang X, Wang K, Yan L, Yu Q, Xia H, Liu Y, Yan C. Multi-stimuli-responsive poly(hydroxyethyl methacrylate-co-N-vinyl pyrrolidone-co-methacrylic acid-co-N-isopropylacryl amide) hydrogel: synthesis, characterization and application in drug release. Iran Polym J. 2019;28(11):957 [Crossref]

15- Tamura R, Said S, de Freitas L, Rubio I. Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies. Diabetol Metab Syndr. 2021;13(1) [Crossref]

16- Tseng C. Differential Effects of Metformin on Immune-Mediated and Androgen-Mediated Non-Cancer Skin Diseases in Diabetes Patients: A Retrospective Cohort Study. Dermatology. 2023;239(4):542 [Crossref]

17- Tseng C. Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study. Front Endocrinol. 2022;13 [Crossref]

18- Hassan S, Bedir E, Hamza A, Ahmed A, Ibrahim N, Abd El‐Ghany M, Khattab N, Emeira B, Salama M, Mohamed E, Fayed D. The dual therapeutic effect of metformin nuclei‐based drugs modified with one of Tulbaghia violacea extract compounds. Applied Organom Chemis. 2022;36(9) [Crossref]